Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 9Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Multiple Myeloma 1Microsatellite Instability 1Melanoma, Cutaneous Malignant 1

Interventions

zaleplon 1relatlimab 1linrodostat 1Nivolumab 1Ipilimumab 1Health Services Needs and Demand 1Clinical Trials, Phase IV as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × relatlimab × 90 days × Clear all
NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
229 enrolled 21 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡